Merck
CN
  • Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.

Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.

Biochemistry (2013-08-09)
Shogo Kamikawaji, Genta Ito, Tomoko Sano, Takeshi Iwatsubo
ABSTRACT

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified in pedigrees of autosomal-dominant familial Parkinson's disease (PARK8). It has been shown that the kinase activity of LRRK2 is required for its neuronal toxicity, although how familial Parkinson mutations affect the function of LRRK2 has not been well characterized. In the present study, we systematically characterized the autophosphorylation of LRRK2 by phosphopeptide mapping and identified Thr1348, Thr1349, and Thr1357 as the major autophosphorylation sites. We found that the autophosphorylation at Thr1357 is downregulated by the Y1699C mutation, possibly through a conformational alteration of the ROC domain. We also found that I2020T mutant LRRK2 undergoes excessive autophosphorylation in cell lysates in vitro at a low concentration of ATP. These results highlight the differential effects of familial mutations in LRRK2 on its conformation and enzymatic properties.

MATERIALS
Product Number
Brand
Product Description

Supelco
L-Threonine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Threonine, BioXtra, ≥99.5% (NT)
Supelco
L-Threonine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Threonine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Threonine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%
SAFC
L-Threonine